IP Library › Granted Patent US 11,827,700
Granted Patent B2
US 11,827,700 · App. 17/095,136 · Granted Nov 28, 2023

Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies

Inventors: Leon F. Garcia-Martinez (Woodinville, WA); Anne Elisabeth Carvalho Jensen (Mill Creek, WA); Katie Anderson (Kirkland, WA); Benjamin H. Dutzar (Seattle, WA); Ethan W. Ojala (Snohomish, WA); Brian R. Kovacevich (Snohomish, WA); John A. Latham (Seattle, WA); Jeffrey T. L. Smith (Dublin, IE)
Assignee: Vitaeris Inc.
C07K16/248A61K39/3955C12N9/60C12N9/64C12N15/81C12P21/02A61K2039/505C07K2317/24C07K2317/34C07K2317/41C07K2317/56C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,827,700
App. No.
17/095,136
Granted
Nov 28, 2023
Kind
B2
Abstract

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Claims (20)

1. A method of treatment of adult respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), sepsis, or systemic inflammatory response syndrome (SIRS) in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody or anti-human IL-6 antibody fragment, wherein the antibody or antibody fragment comprises: a variable light chain (VL) polypeptide comprising the complementarity determining regions (CDRs) of SEQ ID Nos: 4, 5, and 6, and a variable heavy chain (VH) polypeptide comprising the CDRs of SEQ ID Nos: 7, 8 or 120, and 9.

2. The method of claim 1 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 20 and a VH polypeptide of SEQ ID NO: 19.

3. The method of claim 2 , wherein the antibody comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

4. The method of claim 1 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 18, 19, 656, 657 or 658.

5. The method of claim 4 , wherein the antibody comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

6. The method of claim 1 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 20 and a VH polypeptide of SEQ ID NO: 18, 19, 656, 657 or 658.

7. The method of claim 6 , wherein the antibody comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

8. The method of claim 1 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 657.

9. The method of claim 8 , wherein the antibody comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

10. The method of claim 1 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 658.

11. The method of claim 10 , wherein the antibody comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

12. The method of claim 1 , wherein the antibody comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

13. A method of treatment of graft versus host disease (GVHD), reperfusion injury, or transplant rejection in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody or anti-human IL-6 antibody fragment, wherein the antibody or antibody fragment comprises: a variable light chain (VL) polypeptide comprising the complementarity determining regions (CDRs) of SEQ ID Nos: 4, 5, and 6, and a variable heavy chain (VH) polypeptide comprising the CDRs of SEQ ID Nos: 7, 8 or 120, and 9.

14. The method of claim 13 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 20 and a VH polypeptide of SEQ ID NO: 19.

15. The method of claim 13 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 18, 19, 656, 657 or 658.

16. The method of claim 13 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 20 and a VH polypeptide of SEQ ID NO: 18, 19, 656, 657 or 658.

17. The method of claim 13 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 657.

18. The method of claim 13 , wherein the antibody comprises a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 658.

19. The method of claim 13 , wherein the antibody comprises: (a) a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 657 and further comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588; or (b) a VL polypeptide of SEQ ID NO: 651 and a VH polypeptide of SEQ ID NO: 658 and further comprises a light chain constant region polypeptide of SEQ ID NO: 586 and a heavy chain constant region polypeptide of SEQ ID NO: 588.

20. A method of treatment of adult respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), sepsis, or systemic inflammatory response syndrome (SIRS) in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody or anti-human IL- 6 antibody fragment, wherein the antibody or antibody fragment comprises: a variable light chain (VL) polypeptide comprising the complementarity determining regions (CDRs) of SEQ ID Nos: 4, 5, and 6, a variable heavy chain (VH) polypeptide comprising the CDRs of SEQ ID Nos: 7, 8 or 120, and 9, a light chain constant region polypeptide of SEQ ID NO: 586, and a heavy chain constant region polypeptide of SEQ ID NO: 588.